Schedule of Lineage’s Ownership of Outstanding Shares of its Subsidiaries (Details)
|
12 Months Ended |
|
Dec. 31, 2021 |
Sep. 30, 2021 |
| Asterias Biotherapeutics Inc [Member] |
|
|
|
| Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items] |
|
|
|
| Field of business description |
[1] |
Cell
based therapeutics to treat neurological conditions and cancer
|
|
| Noncontrolling interest, ownership percentage by parent |
[1] |
100.00%
|
|
| Cell Cure [Member] |
|
|
|
| Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items] |
|
|
|
| Field of business description |
|
Manufacturing
of Lineage’s cell replacement platform technology
|
|
| Noncontrolling interest, ownership percentage by parent |
[2] |
99.00%
|
|
| Es Cell International Pte Ltd [Member] |
|
|
|
| Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items] |
|
|
|
| Field of business description |
[3] |
Research
and clinical grade cell lines
|
|
| Noncontrolling interest, ownership percentage by parent |
[3] |
100.00%
|
|
| Orthocyte Corporation [Member] |
|
|
|
| Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items] |
|
|
|
| Field of business description |
|
Research
in orthopedic diseases and injuries
|
|
| Noncontrolling interest, ownership percentage by parent |
|
|
99.80%
|
|
|